Drug intelligence / Profile preview

APRTX-005

Development stage
Preclinical
Lead developer
Aperture Therapeutics
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

APRTX-005 is a preclinical-stage antisense oligonucleotide (ASO) candidate being developed by Aperture Therapeutics for the treatment of Parkinson's disease. As an ASO, the molecule is designed to bind to specific messenger RNA (mRNA) sequences to modulate the expression of a target protein involved in the pathogenesis of Parkinson's disease. While the specific molecular target of APRTX-005 is currently undisclosed by the developer, the drug is part of a pipeline focused on neurodegenerative and neurological disorders, utilizing oligonucleotide technology to address microglial-driven neuroinflammation or neuronal vulnerability. It is currently undergoing preclinical evaluation to support potential future clinical development.

Beyond the preview

Go deeper on APRTX-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on APRTX-005.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call